Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

NCT01770483 is registered in ClinicalTrials.gov with Services Institute of Medical Sciences, Pakistan as lead sponsor.

NCT NCT01770483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01770483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2011
Completion date
March 31, 2013
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2, hepatitis c, chronic